Clonal haematopoiesis and dysregulation of the immune system

Nat Rev Immunol. 2023 Sep;23(9):595-610. doi: 10.1038/s41577-023-00843-3. Epub 2023 Mar 20.

Abstract

Age-related diseases are frequently linked to pathological immune dysfunction, including excessive inflammation, autoreactivity and immunodeficiency. Recent analyses of human genetic data have revealed that somatic mutations and mosaic chromosomal alterations in blood cells - a condition known as clonal haematopoiesis (CH) - are associated with ageing and pathological immune dysfunction. Indeed, large-scale epidemiological studies and experimental mouse models have demonstrated that CH can promote cardiovascular disease, chronic obstructive pulmonary disease, chronic liver disease, osteoporosis and gout. The genes most frequently mutated in CH, the epigenetic regulators TET2 and DNMT3A, implicate increased chemokine expression and inflammasome hyperactivation in myeloid cells as a possible mechanistic connection between CH and age-related diseases. In addition, TET2 and DNMT3A mutations in lymphoid cells have been shown to drive methylation-dependent alterations in differentiation and function. Here we review the observational and mechanistic studies describing the connection between CH and pathological immune dysfunction, the effects of CH-associated genetic alterations on the function of myeloid and lymphoid cells, and the clinical and therapeutic implications of CH as a target for immunomodulation.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Clonal Hematopoiesis
  • DNA (Cytosine-5-)-Methyltransferases* / genetics
  • DNA Methyltransferase 3A*
  • Hematopoiesis / genetics
  • Humans
  • Immune System
  • Mice
  • Mutation

Substances

  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A